Arrhythmias & electrophysiology
High-Power Short-Duration Radiofrequency Application for Faster and Safer Pulmonary Vein Isolation: The POWER-FAST III Trial
Corrected 23 Oct 2026: Measure wording clarified; no values changed.
Authors' conclusion
HPSD-70 RFa was noninferior to prevent arrhythmia recurrences, and the incidence of EDELs was similar compared with CPD (25-40) RFa. The embolic events were numerically higher in the HPSD-70 group.
Study context
- Population
- Patients undergoing pulmonary vein isolation301 remained in study
- Participants
- 304 patients
- Comparison
- HPSD-70 vs conventional power delivery (CPD) radiofrequency application for pulmonary vein isolation (PVI)
- Primary endpoint
- Freedom from atrial arrhythmia recurrences and incidence of esophageal thermal lesions (EDELs) after ablation
Methodological details294 (97.7%) underwent ablation, 285 (94.7%) endoscopy, 290 (98.6%) completed follow-up
- 294 (97.7%) underwent ablation, 285 (94.7%) endoscopy, 290 (98.6%) completed follow-up
Primary result
As reported in the abstract
Freedom from recurrences off antiarrhythmic drugs at 12 months
Hazard ratio
1.28
95% CI 0.82–1.99, event not clearly stated
P = 0.28
Events by treatment group
Further findings
Median left atrial dwell time
P = 0.03
Median total RF time for definitive PVI
P < 0.001
Safety
Events
| Outcome | HPSD-70 | CPD (25-40) | P value |
|---|---|---|---|
| Symptomatic embolic events (2 strokes, 1 TIA, 1 splenic infarct) | 4 | 0 | P = 0.056 |
Original publication
High-Power Short-Duration Radiofrequency Application for Faster and Safer Pulmonary Vein Isolation: The POWER-FAST III Trial. JACC Clin Electrophysiol. Published 18 December 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →